

That which is claimed is:

1. A method of screening a human subject in need of treatment for a solid tumor, as an aid in selecting therapy, comprising determining whether the tumor expresses p95<sup>ErbB2</sup>, where expression of p95<sup>ErbB2</sup> indicates said subject is more likely to exhibit a favorable clinical response to treatment that includes a p95<sup>ErbB2</sup> inhibitor, than to treatment that does not include a p95<sup>ErbB2</sup> inhibitor.
2. A method according to claim 1 where expression of p95<sup>ErbB2</sup> in tumor tissue is assessed by immunohistochemical methods.
3. A method according to claim 1 where expression of p95<sup>ErbB2</sup> is assessed by measuring ErbB2 extracellular domain (ECD) in a sample of the subject's serum.
4. A method according to claim 1 where said tumor overexpresses p185<sup>ErbB2</sup>.
5. A method according to claim 1 where said solid tumor is an epithelial tumor.
6. A method according to claim 1 where said tumor is selected from breast, ovarian, colon, head and neck, bladder, renal cell and lung tumors.
7. A method according to claim 1 where said subject has breast cancer.
8. A method according to claim 1 where said subject has previously been treated with a p185<sup>ErbB2</sup> inhibitor.
9. A method according to claim 1 where said subject has previously been treated with trastuzumab.
10. A method of treating a subject with a solid tumor, comprising determining whether the tumor expresses p95<sup>ErbB2</sup>, and treating said subject with a p95<sup>ErbB2</sup> inhibitor if said tumor expresses p95<sup>ErbB2</sup>.

11. A method according to claim 10 where expression of p95<sup>ErbB2</sup> in tumor tissue is assessed by immunohistochemical methods.
12. A method according to claim 10 where expression of p95<sup>ErbB2</sup> is assessed by measuring ErbB2 extracellular domain (ECD) in the subject's serum.
13. A method according to claim 10 where said tumor overexpresses p185<sup>ErbB2</sup>.
14. A method according to claim 10 where said solid tumor is an epithelial tumor.
15. A method according to claim 10 where said tumor is selected from breast, ovarian, colon, head and neck, bladder, renal cell and lung tumors.
16. A method according to claim 10 where said subject has breast cancer.
17. A method according to claim 10 where said subject has previously been treated with a p185<sup>ErbB2</sup> inhibitor.
18. A method according to claim 10 where said subject has previously been treated with trastuzumab.
19. A method according to claim 10 where said p95<sup>ErbB2</sup> inhibitor is GW572016.
20. A method of treating a subject with a solid tumor whose tumor expresses p95<sup>ErbB2</sup>, comprising administering a therapeutically effective amount of a p95<sup>ErbB2</sup> inhibitor to said subject.
21. A method according to claim 20, where said subject has breast cancer.
22. A method according to claim 20, where said p95<sup>ErbB2</sup> inhibitor is GW572016.
23. A method according to claim 20 where said subject has previously been treated with trastuzumab.

24. A method of treating a subject with breast cancer that is resistant to treatment with a p185<sup>ErbB2</sup> inhibitor that binds to the extracellular domain of ErbB2 and whose tumor expresses p95<sup>ErbB2</sup>, comprising administering a therapeutically effective amount of a p95<sup>ErbB2</sup> inhibitor to said subject.
25. A method according to claim 24, where said p95<sup>ErbB2</sup> inhibitor is GW572016.
26. A method according to claim 24 where said subject has previously been treated with trastuzumab.
27. A method of screening a subject in need of treatment for breast cancer to determine suitability for treatment with a p185<sup>ErbB2</sup> inhibitor that binds to the extracellular domain of ErbB2, comprising determining whether said tumor expresses an elevated level of p95<sup>ErbB2</sup>, where an elevated level of p95<sup>ErbB2</sup> indicates that said subject should not be treated with a p185<sup>ErbB2</sup> inhibitor in the absence of treatment with a p95<sup>ErbB2</sup> inhibitor.
28. A method according to claim 27, further comprising treating said subject with a treatment selected from (a) a p185<sup>ErbB2</sup> inhibitor, (b) a combined a p185<sup>ErbB2</sup> inhibitor

\* \* \*